

PRESS RELEASE

Gradientech Achieves Key Market Milestone as QuickMIC® Enters Routine Clinical Use in Austria

Uppsala, Sweden, November 17, 2025. The diagnostics company Gradientech and its distributor Biomedica Medizinprodukte, today announce the successful installation of the QuickMIC® system for ultra-rapid antibiotic susceptibility testing (AST) at the Wels-Grieskirchen Clinic in Austria, marking a pivotal step in the company's European expansion.

The Wels-Grieskirchen Clinic is Austria's largest hospital in the Wels region with 35 medical departments and more than 1,200 beds. The hospital is an essential provider of comprehensive medical care in Upper Austria. Through its competence centres, the hospital bundles interdisciplinary know-how and enables interdisciplinary diagnoses and treatments for the benefit of patients.

The installation represents a strong validation of both Gradientech's innovative technology and Biomedica's commitment to advancing clinical microbiology across Central Europe. It underscores growing market confidence in the QuickMIC platform's ability to deliver rapid, precise AST results, empowering hospitals to improve infection management and sepsis patient outcomes.

"This is a significant milestone for the Austrian market. With hospital-acquired infections continuing to pose a major healthcare challenge, the QuickMIC system offers laboratories a powerful tool to obtain reliable results in a fraction of the time compared to traditional methods. The system's modular design and scalability make it ideally suited for hospitals seeking to enhance diagnostic efficiency and optimise antibiotic stewardship programs", says Avdo Novalija, Business Development at Biomedica Medizinprodukte.

Biomedica Medizinprodukte has been distributing in vitro diagnostics, medical devices, clinical IT and life sciences products for over 40 years, and is the exclusive distributor of the QuickMIC system in 13 countries across Central and Eastern Europe.

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.